secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioAge Labs, Inc. (BIOA)
CIK:        0001709941
Form:       8-K
Filed at:   2026-08-05T20:55:14+00:00
Accession:  0001193125-26-335368
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioAge Labs Q2 net loss $26.1M; dosed first participant in Phase 2 BGE-102 trial
--------------------------------------------------------------------------------

- Net loss $26.1M ($0.58/share) vs $21.6M ($0.60/share) in Q2 2025; R&D spend up $4.6M to $24.4M.
- First participant dosed in QUELL-CV Phase 2 trial of BGE-102 (NLRP3 inhibitor); topline data expected H2 2026.
- Cash, cash equivalents, and marketable securities $381.3M as of June 30, 2026; sufficient through 2029.
- QUELL-DME Phase 1b/2a trial in diabetic macular edema planned to start mid-2026, data mid-2027.
- Collaboration revenue flat at $2.4M; APJ agonist IND planned by year-end 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1709941/000119312526335368/0001193125-26-335368-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1709941/000119312526335368/bioa-20260805.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-335368

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer